176 related articles for article (PubMed ID: 29681389)
41. Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies.
Pai RK; Mullins FM; Kim YH; Kong CS
Cancer; 2008 Oct; 114(5):323-32. PubMed ID: 18798522
[TBL] [Abstract][Full Text] [Related]
42. KIR3DL2 in cutaneous T-cell lymphoma: from a promising biomarker to a potential therapeutic target.
Sun J; Wang Y
Br J Dermatol; 2020 Jun; 182(6):1325-1326. PubMed ID: 31808144
[No Abstract] [Full Text] [Related]
43. [Epitheliotropic lymphomas: better identification for improved treatment].
Bagot M
Bull Acad Natl Med; 2010 Oct; 194(7):1365-72. PubMed ID: 22043631
[TBL] [Abstract][Full Text] [Related]
44. New and established treatment options for mycosis fungoides and Sézary syndrome - an update.
Dugas-Breit S; Schulze HJ; Hallermann C
J Dtsch Dermatol Ges; 2014 Jul; 12(7):561-9. PubMed ID: 24889480
[TBL] [Abstract][Full Text] [Related]
45. Skewed expression of activation, differentiation and homing-related antigens in circulating cells from patients with cutaneous T cell lymphoma associated with CD7- T helper lymphocytes expansion.
Scala E; Russo G; Cadoni S; Narducci MG; Girardelli CR; De Pità O; Puddu P
J Invest Dermatol; 1999 Oct; 113(4):622-7. PubMed ID: 10504451
[TBL] [Abstract][Full Text] [Related]
46. Mogamulizumab-associated rash: A challenging case report and literature review.
Martínez-Fernández S; Suh-Oh HJ; Couselo-Rodríguez C; Soto-García D; Álvarez C; Flórez Á
Australas J Dermatol; 2023 May; 64(2):e191-e193. PubMed ID: 36896897
[No Abstract] [Full Text] [Related]
47. Pentostatin treatment of cutaneous T-cell lymphoma.
Dearden C; Matutes E; Catovsky D
Oncology (Williston Park); 2000 Jun; 14(6 Suppl 2):37-40. PubMed ID: 10887643
[TBL] [Abstract][Full Text] [Related]
48. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
[TBL] [Abstract][Full Text] [Related]
49. [Cells in the epidermotropic lymphomas (mycosis fungoides and Sézary syndrome. Study using monoclonal antibodies].
Thivolet J; Schmitt D; Souteyrand P; Brochier J
Nouv Presse Med; 1982 Oct; 11(41):3033-8. PubMed ID: 6755391
[TBL] [Abstract][Full Text] [Related]
50. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
[TBL] [Abstract][Full Text] [Related]
51. PLCγ1/PKCθ Downstream Signaling Controls Cutaneous T-Cell Lymphoma Development and Progression.
García-Díaz N; Casar B; Alonso-Alonso R; Quevedo L; Rodríguez M; Ruso-Julve F; Esteve-Codina A; Gut M; Gru AA; González-Vela MC; Gut I; Rodriguez-Peralto JL; Varela I; Ortiz-Romero PL; Piris MA; Vaqué JP
J Invest Dermatol; 2022 May; 142(5):1391-1400.e15. PubMed ID: 34687742
[TBL] [Abstract][Full Text] [Related]
52. Leonine facies (LF) and mycosis fungoides (MF): A single-center study and systematic review of the literature.
Brown DN; Wieser I; Wang C; Dabaja BS; Duvic M
J Am Acad Dermatol; 2015 Dec; 73(6):976-86. PubMed ID: 26476898
[TBL] [Abstract][Full Text] [Related]
53. [Comparative analysis of the expression of cell adhesion molecules in cutaneous T-cell lymphomas (mycosis fungoides/Sézary syndrome) and inflammatory skin diseases].
López-Lerma I; Estrach MT
Actas Dermosifiliogr; 2010 Dec; 101(10):866-77. PubMed ID: 21159263
[TBL] [Abstract][Full Text] [Related]
54. Primary cutaneous B-cell lymphomas - clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome.
Golling P; Cozzio A; Dummer R; French L; Kempf W
Leuk Lymphoma; 2008 Jun; 49(6):1094-103. PubMed ID: 18569636
[TBL] [Abstract][Full Text] [Related]
55. New aspects of the clinicopathological features and treatment of mycosis fungoides and Sézary syndrome.
Furue M; Kadono T
J Dermatol; 2015 Oct; 42(10):941-4. PubMed ID: 26432429
[TBL] [Abstract][Full Text] [Related]
56. Cutaneous T-cell lymphoma epidemiology: patients providing the power.
Lessin SR
Arch Dermatol; 2007 Jul; 143(7):916-8. PubMed ID: 17638738
[No Abstract] [Full Text] [Related]
57. Rational therapy for cutaneous T-cell lymphomas in the 1990s. Fact or fancy?
Bunn PA
Arch Dermatol; 1995 May; 131(5):603-5. PubMed ID: 7537952
[No Abstract] [Full Text] [Related]
58. [Current therapy concepts in cutaneous T-cell lymphomas].
Nestle FO; Häffner AC; Schmid MH; Dummer R; Burg G
Schweiz Med Wochenschr; 1997 Feb; 127(8):311-20. PubMed ID: 9157537
[TBL] [Abstract][Full Text] [Related]
59. [Diagnosis and treatment for cutaneous T-cell lymphomas].
Hamada T; Iwatsuki K
Nihon Rinsho; 2012 Apr; 70 Suppl 2():537-43. PubMed ID: 23134012
[No Abstract] [Full Text] [Related]
60. Biological insights into the pathogenesis of cutaneous T-cell lymphomas (CTCL).
Whittaker S
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S3-6. PubMed ID: 16516668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
